retlirafusp alfa + XELOX + bevacizumab

The combination regimen **retlirafusp alfa + XELOX + bevacizumab** is an investigational therapeutic approach being evaluated for the first-line treatment of advanced or metastatic colorectal cancer (mCRC), particularly in patients with RAS mutations and colorectal cancer liver metastases (CRCLM). This regimen combines **retlirafusp alfa** (SHR-1701), a bifunctional fusion protein that simultaneously blocks the PD-L1 immune checkpoint and neutralizes TGF-β; **XELOX** (capecitabine and oxaliplatin), a standard cytotoxic chemotherapy regimen; and **bevacizumab**, an anti-VEGF monoclonal antibody. By targeting multiple pathways—immune checkpoint inhibition, TGF-β-mediated immunosuppression/exclusion, tumor angiogenesis, and DNA replication—this combination aims to overcome the typical immunotherapy resistance observed in microsatellite-stable (MSS) colorectal cancers.

Other names

SHR-1701 + XELOX + bevacizumabSHR-1701 + CAPOX + bevacizumabretlirafusp alfa + CAPOX + bevacizumabretlirafusp alfa + capecitabine + oxaliplatin + bevacizumabSHR-1701 + capecitabine + oxaliplatin + bevacizumab